U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C9H13NO2
Molecular Weight 167.2054
Optical Activity UNSPECIFIED
Defined Stereocenters 1 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of PHENYLEPHRINE

SMILES

CNC[C@@]([H])(c1cccc(c1)O)O

InChI

InChIKey=SONNWYBIRXJNDC-VIFPVBQESA-N
InChI=1S/C9H13NO2/c1-10-6-9(12)7-3-2-4-8(11)5-7/h2-5,9-12H,6H2,1H3/t9-/m0/s1

HIDE SMILES / InChI

Molecular Formula C9H13NO2
Molecular Weight 167.2054
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 1 / 1
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Curator's Comment:: Description was created based on several sources, including http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/204300lbl.pdf and https://www.drugs.com/pro/phenylephrine-and-chlorpheniramine-tablets.html

Phenylephrine is a powerful vasoconstrictor. It is used as a nasal decongestant and cardiotonic agent. Phenylephrine is a postsynaptic α1-receptor agonist with little effect on β-receptors of the heart. Parenteral administration of phenylephrine causes a rise in systolic and diastolic pressures, a slight decrease in cardiac output, and a considerable increase in peripheral resistance; most vascular beds are constricted, and renal, splanchnic, cutaneous, and limb blood flows are reduced while coronary blood flow is increased. Phenelephrine also causes pulmonary vessel constriction and subsequent increase in pulmonary arterial pressure. Vasoconstriction in the mucosa of the respiratory tract leads to decreased edema and increased drainage of sinus cavities. In general, α1-adrenergic receptors mediate contraction and hypertrophic growth of smooth muscle cells. α1-receptors are 7-transmembrane domain receptors coupled to G proteins, Gq/11. Three α1-receptor subtypes, which share approximately 75% homology in their transmembrane domains, have been identified: α1A (chromosome 8), α1B (chromosome 5), and α1D (chromosome 20). Phenylephrine appears to act similarly on all three receptor subtypes. All three receptor subtypes appear to be involved in maintaining vascular tone. The α1A-receptor maintains basal vascular tone while the α1B-receptor mediates the vasocontrictory effects of exogenous α1-agonists. Activation of the α1-receptor activates Gq-proteins, which results in intracellular stimulation of phospholipases C, A2, and D. This results in mobilization of Ca2+ from intracellular stores, activation of mitogen-activated kinase and PI3 kinase pathways and subsequent vasoconstriction. Phenylephrine produces its local and systemic actions by acting on α1-adrenergic receptors peripheral vascular smooth muscle. Stimulation of the α1-adrenergic receptors results in contraction arteriolar smooth muscle in the periphery. Phenylephrine decreases nasal congestion by acting on α1-adrenergic receptors in the arterioles of the nasal mucosa to produce constriction; this leads to decreased edema and increased drainage of the sinus cavities. Phenylephrine is mainly used to treat nasal congestion, but may also be useful in treating hypotension and shock, hypotension during spinal anaesthesia, prolongation of spinal anaesthesia, paroxysmal supraventricular tachycardia, symptomatic relief of external or internal hemorrhoids, and to increase blood pressure as an aid in the diagnosis of heart murmurs.

CNS Activity

Curator's Comment:: Phenylephrine does not cross the blood–brain barrier

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
55.0 nM [EC50]
5.9 nM [EC50]
154.88 nM [EC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
VAZCULEP

Approved Use

VAZCULEP (phenylephrine hydrochloride) is indicated for the treatment of clinically important hypotension resulting primarily from vasodilation in the setting of anesthesia.

Launch Date

-5.05007997E11
Diagnostic
Phenylephrine Hydrochloride Ophthalmic Solution

Approved Use

Indicated to dilate the pupil

Launch Date

-9.7839363E11
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
2959 pg/mL
20 mg single, oral
dose: 20 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
PHENYLEPHRINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
4492 pg/mL
30 mg single, oral
dose: 30 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
PHENYLEPHRINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
1354 pg/mL
10 mg single, oral
dose: 10 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
PHENYLEPHRINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
2346 pg × h/mL
20 mg single, oral
dose: 20 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
PHENYLEPHRINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
3900 pg × h/mL
30 mg single, oral
dose: 30 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
PHENYLEPHRINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
955.8 pg × h/mL
10 mg single, oral
dose: 10 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
PHENYLEPHRINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
1.93 h
20 mg single, oral
dose: 20 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
PHENYLEPHRINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
1.64 h
30 mg single, oral
dose: 30 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
PHENYLEPHRINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
1.89 h
10 mg single, oral
dose: 10 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
PHENYLEPHRINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
Doses

Doses

DosePopulationAdverse events​
10 mg 1 times / day multiple, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg, 1 times / day
Sources:
unhealthy, 34 years
n = 1
Health Status: unhealthy
Age Group: 34 years
Sex: M
Population Size: 1
Sources:
Disc. AE: Ischemic colitis...
AEs leading to
discontinuation/dose reduction:
Ischemic colitis (acute)
Sources:
40 mg 6 times / day multiple, oral
Highest studied dose
Dose: 40 mg, 6 times / day
Route: oral
Route: multiple
Dose: 40 mg, 6 times / day
Sources:
unhealthy, 37.5 years (range: 19.0 - 77.0 years)
n = 112
Health Status: unhealthy
Condition: Seasonal Allergic Rhinitis
Age Group: 37.5 years (range: 19.0 - 77.0 years)
Sex: M+F
Population Size: 112
Sources:
Disc. AE: Chest pain, Jaw pain...
Other AEs: Nervous system disorders, Headache...
AEs leading to
discontinuation/dose reduction:
Chest pain (1 patient)
Jaw pain (1 patient)
Other AEs:
Nervous system disorders (3.6%)
Headache (2.7%)
Gastrointestinal disorders (8%)
Dry mouth (2.7%)
Nausea (3.6%)
Sources:
10 % 3 times / day multiple, ophthalmic
Recommended
Dose: 10 %, 3 times / day
Route: ophthalmic
Route: multiple
Dose: 10 %, 3 times / day
Sources:
healthy, > 1 year
Health Status: healthy
Age Group: > 1 year
Sources:
Other AEs: Eye pain, Blurred vision...
Other AEs:
Eye pain
Blurred vision
Photophobia
Allergic conjunctivitis
Sources:
250 ug single, intravenous
Recommended
Dose: 250 ug
Route: intravenous
Route: single
Dose: 250 ug
Sources:
unhealthy, adult
AEs

AEs

AESignificanceDosePopulation
Ischemic colitis acute
Disc. AE
10 mg 1 times / day multiple, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg, 1 times / day
Sources:
unhealthy, 34 years
n = 1
Health Status: unhealthy
Age Group: 34 years
Sex: M
Population Size: 1
Sources:
Chest pain 1 patient
Disc. AE
40 mg 6 times / day multiple, oral
Highest studied dose
Dose: 40 mg, 6 times / day
Route: oral
Route: multiple
Dose: 40 mg, 6 times / day
Sources:
unhealthy, 37.5 years (range: 19.0 - 77.0 years)
n = 112
Health Status: unhealthy
Condition: Seasonal Allergic Rhinitis
Age Group: 37.5 years (range: 19.0 - 77.0 years)
Sex: M+F
Population Size: 112
Sources:
Jaw pain 1 patient
Disc. AE
40 mg 6 times / day multiple, oral
Highest studied dose
Dose: 40 mg, 6 times / day
Route: oral
Route: multiple
Dose: 40 mg, 6 times / day
Sources:
unhealthy, 37.5 years (range: 19.0 - 77.0 years)
n = 112
Health Status: unhealthy
Condition: Seasonal Allergic Rhinitis
Age Group: 37.5 years (range: 19.0 - 77.0 years)
Sex: M+F
Population Size: 112
Sources:
Dry mouth 2.7%
40 mg 6 times / day multiple, oral
Highest studied dose
Dose: 40 mg, 6 times / day
Route: oral
Route: multiple
Dose: 40 mg, 6 times / day
Sources:
unhealthy, 37.5 years (range: 19.0 - 77.0 years)
n = 112
Health Status: unhealthy
Condition: Seasonal Allergic Rhinitis
Age Group: 37.5 years (range: 19.0 - 77.0 years)
Sex: M+F
Population Size: 112
Sources:
Headache 2.7%
40 mg 6 times / day multiple, oral
Highest studied dose
Dose: 40 mg, 6 times / day
Route: oral
Route: multiple
Dose: 40 mg, 6 times / day
Sources:
unhealthy, 37.5 years (range: 19.0 - 77.0 years)
n = 112
Health Status: unhealthy
Condition: Seasonal Allergic Rhinitis
Age Group: 37.5 years (range: 19.0 - 77.0 years)
Sex: M+F
Population Size: 112
Sources:
Nausea 3.6%
40 mg 6 times / day multiple, oral
Highest studied dose
Dose: 40 mg, 6 times / day
Route: oral
Route: multiple
Dose: 40 mg, 6 times / day
Sources:
unhealthy, 37.5 years (range: 19.0 - 77.0 years)
n = 112
Health Status: unhealthy
Condition: Seasonal Allergic Rhinitis
Age Group: 37.5 years (range: 19.0 - 77.0 years)
Sex: M+F
Population Size: 112
Sources:
Nervous system disorders 3.6%
40 mg 6 times / day multiple, oral
Highest studied dose
Dose: 40 mg, 6 times / day
Route: oral
Route: multiple
Dose: 40 mg, 6 times / day
Sources:
unhealthy, 37.5 years (range: 19.0 - 77.0 years)
n = 112
Health Status: unhealthy
Condition: Seasonal Allergic Rhinitis
Age Group: 37.5 years (range: 19.0 - 77.0 years)
Sex: M+F
Population Size: 112
Sources:
Gastrointestinal disorders 8%
40 mg 6 times / day multiple, oral
Highest studied dose
Dose: 40 mg, 6 times / day
Route: oral
Route: multiple
Dose: 40 mg, 6 times / day
Sources:
unhealthy, 37.5 years (range: 19.0 - 77.0 years)
n = 112
Health Status: unhealthy
Condition: Seasonal Allergic Rhinitis
Age Group: 37.5 years (range: 19.0 - 77.0 years)
Sex: M+F
Population Size: 112
Sources:
Allergic conjunctivitis
10 % 3 times / day multiple, ophthalmic
Recommended
Dose: 10 %, 3 times / day
Route: ophthalmic
Route: multiple
Dose: 10 %, 3 times / day
Sources:
healthy, > 1 year
Health Status: healthy
Age Group: > 1 year
Sources:
Blurred vision
10 % 3 times / day multiple, ophthalmic
Recommended
Dose: 10 %, 3 times / day
Route: ophthalmic
Route: multiple
Dose: 10 %, 3 times / day
Sources:
healthy, > 1 year
Health Status: healthy
Age Group: > 1 year
Sources:
Eye pain
10 % 3 times / day multiple, ophthalmic
Recommended
Dose: 10 %, 3 times / day
Route: ophthalmic
Route: multiple
Dose: 10 %, 3 times / day
Sources:
healthy, > 1 year
Health Status: healthy
Age Group: > 1 year
Sources:
Photophobia
10 % 3 times / day multiple, ophthalmic
Recommended
Dose: 10 %, 3 times / day
Route: ophthalmic
Route: multiple
Dose: 10 %, 3 times / day
Sources:
healthy, > 1 year
Health Status: healthy
Age Group: > 1 year
Sources:
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG

OverviewOther

Other InhibitorOther SubstrateOther Inducer

Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
yes
PubMed

PubMed

TitleDatePubMed
Characterization of human recombinant alpha(2A)-adrenoceptors expressed in Chinese hamster lung cells using intracellular Ca(2+) changes: evidence for cross-talk between recombinant alpha(2A)- and native alpha(1)-adrenoceptors.
2000 Apr
Targeted inhibition of calcineurin prevents agonist-induced cardiomyocyte hypertrophy.
2000 Feb 1
Neuropeptide Y (NPY) potentiates phenylephrine-induced mitogen-activated protein kinase activation in primary cardiomyocytes via NPY Y5 receptors.
2000 Feb 15
Calcineurin-mediated hypertrophy protects cardiomyocytes from apoptosis in vitro and in vivo: An apoptosis-independent model of dilated heart failure.
2000 Feb 18
Inhibitory regulation of hypertrophy by endogenous atrial natriuretic peptide in cultured cardiac myocytes.
2000 Jan
Bupivacaine inhibits baroreflex control of heart rate in conscious rats.
2000 Jan
Minidose bupivacaine-fentanyl spinal anesthesia for surgical repair of hip fracture in the aged.
2000 Jan
Fine structure and plasticity of barosensitive neurons in the nucleus of solitary tract.
2000 Jul 3
Gene transfer of endothelial nitric oxide synthase improves relaxation of carotid arteries from diabetic rabbits.
2000 Mar 7
Central control of cardiac baroreflex responses during peripheral hyperosmolality.
2000 May
The effect of phenylephrine on pain and flare intensity in eyes with uveitis.
2000 Oct
Heparin-mediated hypotension associated with cardiac surgery.
2000 Sep
Influence of a multideficient diet from northeastern Brazil on resting blood pressure and baroreflex sensitivity in conscious, freely moving rats.
2001 Feb
Nitric oxide-mediated arteriolar dilation after endothelial deformation.
2001 Feb
Regulation of mitogen-activated protein kinases in cardiac myocytes through the small G protein Rac1.
2001 Feb
Heat, but not mechanical hyperalgesia, following adrenergic injections in normal human skin.
2001 Feb 1
Flow (shear stress)-induced endothelium-dependent dilation is altered in mice lacking the gene encoding for dystrophin.
2001 Feb 13
The transient receptor potential protein homologue TRP6 is the essential component of vascular alpha(1)-adrenoceptor-activated Ca(2+)-permeable cation channel.
2001 Feb 16
Ras regulates NFAT3 activity in cardiac myocytes.
2001 Feb 2
Depletion of phosphatidylinositol 4,5-bisphosphate by activation of phospholipase C-coupled receptors causes slow inhibition but not desensitization of G protein-gated inward rectifier K+ current in atrial myocytes.
2001 Feb 23
Nitric oxide contributes to vascular smooth muscle relaxation in contracting fast-twitch muscles.
2001 Feb 7
Methylene blue as a successful treatment alternative for pharmacologically induced priapism.
2001 Jan
A N-terminal PTHrP peptide fragment void of a PTH/PTHrP-receptor binding domain activates cardiac ET(A) receptors.
2001 Jan
Involvement of Ca2+ -activated K+ channels in ginsenosides-induced aortic relaxation in rats.
2001 Jan
Effect of dietary vitamin E supplementation on vascular reactivity of thoracic aorta in streptozotocin-diabetic rats.
2001 Jan
Should the angiotensin II antagonists be discontinued before surgery?
2001 Jan
Effects of acute and chronic hypertension on the labyrinthine barriers in rat.
2001 Jan
CYP4A1 antisense oligonucleotide reduces mesenteric vascular reactivity and blood pressure in SHR.
2001 Jan
Acute hypertension inhibits thirst stimulated by ANG II, hyperosmolality, or hypovolemia in rats.
2001 Jan
[Ca(2+)](i) signaling in renal arterial smooth muscle cells of pregnant rat is enhanced during inhibition of NOS.
2001 Jan
Substance P and NPY differentially potentiate ATP and adrenergic stimulated vasopressin and oxytocin release.
2001 Jan
Endothelin and nitric oxide mediate reduced myogenic reactivity of small renal arteries from pregnant rats.
2001 Jan
Receptor reserve analysis of the human alpha(2C)-adrenoceptor using.
2001 Jan 12
Catecholamine inotropes as growth factors for Staphylococcus epidermidis and other coagulase-negative staphylococci.
2001 Jan 15
Relaxation of rat aorta by adenosine in diabetes with and without hypertension: role of endothelium.
2001 Jan 19
Phosphatidylinositol 4,5-bisphosphate is acting as a signal molecule in alpha(1)-adrenergic pathway via the modulation of acetylcholine-activated K(+) channels in mouse atrial myocytes.
2001 Jan 5
In vivo regulation of Na/Ca exchanger expression by adrenergic effectors.
2001 Mar
Endothelial cell protein kinase G inhibits release of EDHF through a PKG-sensitive cation channel.
2001 Mar
Reciprocal regulation of cGMP-mediated vasorelaxation by soluble and particulate guanylate cyclases.
2001 Mar
Endogenous estrogen mediates vascular reactivity and distensibility in pregnant rat mesenteric arteries.
2001 Mar
Topical phenylephrine increases anal canal resting pressure in patients with faecal incontinence.
2001 Mar
Regulation of slow wave frequency by IP(3)-sensitive calcium release in the murine small intestine.
2001 Mar
EDHF contributes to strain-related differences in pulmonary arterial relaxation in rats.
2001 Mar
Patents

Sample Use Guides

In Vivo Use Guide
Curator's Comment:: Also used as Ophthalmic Solution or oral tablets http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/203510s000lbl.pdf https://www.drugs.com/dosage/chlorpheniramine-phenylephrine.html
VAZCULEP (phenylephrine hydrochloride) Injection, 10 mg/mL, is injected intravenously either as a bolus or in a dilute solution as a continuous infusion. Dilute before administration. Dosing for treatment of hypotension during anesthesia Bolus intravenous injection: 40 mcg to 100 mcg every 1-2 minutes as needed, not to exceed 200 mcg. Intravenous infusion: 10 mcg/min to 35 mcg/min, titrating to effect, not to exceed 200 mcg/min.
Route of Administration: Intravenous
The hypertrophic phenotype of neonatal rat cardiomyocyte cultures (cardiomyocyte size, sarcomeric organization, total protein synthesis, c-fos expression) mediated by phenylephrine (10 uM) was counteracted by the selective A1 receptor agonist
Substance Class Chemical
Created
by admin
on Fri Jun 25 21:11:36 UTC 2021
Edited
by admin
on Fri Jun 25 21:11:36 UTC 2021
Record UNII
1WS297W6MV
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
PHENYLEPHRINE
EP   HSDB   INN   MART.   MI   VANDF   WHO-DD  
INN  
Official Name English
J8.601K
Code English
M-SYMPATHOL
Common Name English
M-SYNEPHRINE
Common Name English
AB-101 (PHENYLEPHRINE)
Code English
(R)-PHENYLEPHRINE
Common Name English
(-)-3 HYDROXY-.ALPHA.-((METHYLAMINO)METHYL)BENZENEMETHANOL
Systematic Name English
PHENYLEPHRINE [EP]
Common Name English
PHENYLEPHRINE, (R)-
Common Name English
PHENYLEPHRINE MINIMS
Brand Name English
R(-)-MEZATON
Common Name English
PHENYLEPHRINE [HSDB]
Common Name English
(-)-1-(3-HYDROXYPHENYL)-2-METHYLAMINOETHANOL
Systematic Name English
M-OXEDRINE
Common Name English
PHENYLEPHRINE [WHO-DD]
Common Name English
PHENYLEPHRINE [VANDF]
Common Name English
PHENYLEPHRINE [MI]
Common Name English
META-SYNEPHRINE
Common Name English
PHENYLEPHRINE [INN]
Common Name English
M-SYMPATOL
Common Name English
PHENYLEPHRINE [EP MONOGRAPH]
Common Name English
METASYNEPHRINE
Common Name English
(-)-PHENYLEPHRINE
Common Name English
PHENYLEPHRINE [MART.]
Common Name English
Classification Tree Code System Code
LIVERTOX 773
Created by admin on Fri Jun 25 21:11:36 UTC 2021 , Edited by admin on Fri Jun 25 21:11:36 UTC 2021
WHO-VATC QR01BA03
Created by admin on Fri Jun 25 21:11:36 UTC 2021 , Edited by admin on Fri Jun 25 21:11:36 UTC 2021
WHO-VATC QS01FB01
Created by admin on Fri Jun 25 21:11:36 UTC 2021 , Edited by admin on Fri Jun 25 21:11:36 UTC 2021
WHO-VATC QR01AA04
Created by admin on Fri Jun 25 21:11:36 UTC 2021 , Edited by admin on Fri Jun 25 21:11:36 UTC 2021
WHO-VATC QC01CA06
Created by admin on Fri Jun 25 21:11:36 UTC 2021 , Edited by admin on Fri Jun 25 21:11:36 UTC 2021
WHO-ATC R01BA03
Created by admin on Fri Jun 25 21:11:36 UTC 2021 , Edited by admin on Fri Jun 25 21:11:36 UTC 2021
WHO-ATC R01AB01
Created by admin on Fri Jun 25 21:11:36 UTC 2021 , Edited by admin on Fri Jun 25 21:11:36 UTC 2021
WHO-ATC R01BA53
Created by admin on Fri Jun 25 21:11:36 UTC 2021 , Edited by admin on Fri Jun 25 21:11:36 UTC 2021
WHO-VATC QS01GA55
Created by admin on Fri Jun 25 21:11:36 UTC 2021 , Edited by admin on Fri Jun 25 21:11:36 UTC 2021
WHO-ATC C01CA06
Created by admin on Fri Jun 25 21:11:36 UTC 2021 , Edited by admin on Fri Jun 25 21:11:36 UTC 2021
WHO-ATC S01BB01
Created by admin on Fri Jun 25 21:11:36 UTC 2021 , Edited by admin on Fri Jun 25 21:11:36 UTC 2021
WHO-VATC QS01GA05
Created by admin on Fri Jun 25 21:11:36 UTC 2021 , Edited by admin on Fri Jun 25 21:11:36 UTC 2021
WHO-VATC QR01AB01
Created by admin on Fri Jun 25 21:11:36 UTC 2021 , Edited by admin on Fri Jun 25 21:11:36 UTC 2021
WHO-ATC S01FB51
Created by admin on Fri Jun 25 21:11:36 UTC 2021 , Edited by admin on Fri Jun 25 21:11:36 UTC 2021
WHO-ATC S01FB01
Created by admin on Fri Jun 25 21:11:36 UTC 2021 , Edited by admin on Fri Jun 25 21:11:36 UTC 2021
FDA ORPHAN DRUG 147201
Created by admin on Fri Jun 25 21:11:36 UTC 2021 , Edited by admin on Fri Jun 25 21:11:36 UTC 2021
WHO-VATC QR01BA53
Created by admin on Fri Jun 25 21:11:36 UTC 2021 , Edited by admin on Fri Jun 25 21:11:36 UTC 2021
NCI_THESAURUS C29709
Created by admin on Fri Jun 25 21:11:36 UTC 2021 , Edited by admin on Fri Jun 25 21:11:36 UTC 2021
WHO-ATC S01GA55
Created by admin on Fri Jun 25 21:11:36 UTC 2021 , Edited by admin on Fri Jun 25 21:11:36 UTC 2021
NDF-RT N0000186105
Created by admin on Fri Jun 25 21:11:36 UTC 2021 , Edited by admin on Fri Jun 25 21:11:36 UTC 2021
WHO-ATC R01AA04
Created by admin on Fri Jun 25 21:11:36 UTC 2021 , Edited by admin on Fri Jun 25 21:11:36 UTC 2021
WHO-ATC S01GA05
Created by admin on Fri Jun 25 21:11:36 UTC 2021 , Edited by admin on Fri Jun 25 21:11:36 UTC 2021
FDA ORPHAN DRUG 359011
Created by admin on Fri Jun 25 21:11:36 UTC 2021 , Edited by admin on Fri Jun 25 21:11:36 UTC 2021
Code System Code Type Description
NCI_THESAURUS
C62067
Created by admin on Fri Jun 25 21:11:36 UTC 2021 , Edited by admin on Fri Jun 25 21:11:36 UTC 2021
PRIMARY
CAS
59-42-7
Created by admin on Fri Jun 25 21:11:36 UTC 2021 , Edited by admin on Fri Jun 25 21:11:36 UTC 2021
PRIMARY
RXCUI
8163
Created by admin on Fri Jun 25 21:11:36 UTC 2021 , Edited by admin on Fri Jun 25 21:11:36 UTC 2021
PRIMARY
MESH
D010656
Created by admin on Fri Jun 25 21:11:36 UTC 2021 , Edited by admin on Fri Jun 25 21:11:36 UTC 2021
PRIMARY
ChEMBL
CHEMBL1215
Created by admin on Fri Jun 25 21:11:36 UTC 2021 , Edited by admin on Fri Jun 25 21:11:36 UTC 2021
PRIMARY
RXCUI
325517
Created by admin on Fri Jun 25 21:11:36 UTC 2021 , Edited by admin on Fri Jun 25 21:11:36 UTC 2021
ALTERNATIVE
EPA CompTox
59-42-7
Created by admin on Fri Jun 25 21:11:36 UTC 2021 , Edited by admin on Fri Jun 25 21:11:36 UTC 2021
PRIMARY
IUPHAR
485
Created by admin on Fri Jun 25 21:11:36 UTC 2021 , Edited by admin on Fri Jun 25 21:11:36 UTC 2021
PRIMARY
EVMPD
SUB09788MIG
Created by admin on Fri Jun 25 21:11:36 UTC 2021 , Edited by admin on Fri Jun 25 21:11:36 UTC 2021
PRIMARY
HSDB
3383
Created by admin on Fri Jun 25 21:11:36 UTC 2021 , Edited by admin on Fri Jun 25 21:11:36 UTC 2021
PRIMARY
DRUG BANK
DB00388
Created by admin on Fri Jun 25 21:11:36 UTC 2021 , Edited by admin on Fri Jun 25 21:11:36 UTC 2021
PRIMARY
LACTMED
Phenylephrine
Created by admin on Fri Jun 25 21:11:36 UTC 2021 , Edited by admin on Fri Jun 25 21:11:36 UTC 2021
PRIMARY
PUBCHEM
6041
Created by admin on Fri Jun 25 21:11:36 UTC 2021 , Edited by admin on Fri Jun 25 21:11:36 UTC 2021
PRIMARY
ECHA (EC/EINECS)
200-424-8
Created by admin on Fri Jun 25 21:11:36 UTC 2021 , Edited by admin on Fri Jun 25 21:11:36 UTC 2021
PRIMARY
DRUG CENTRAL
2146
Created by admin on Fri Jun 25 21:11:36 UTC 2021 , Edited by admin on Fri Jun 25 21:11:36 UTC 2021
PRIMARY
NDF-RT
N0000009917
Created by admin on Fri Jun 25 21:11:36 UTC 2021 , Edited by admin on Fri Jun 25 21:11:36 UTC 2021
PRIMARY Adrenergic alpha1-Agonists [MoA]
FDA UNII
1WS297W6MV
Created by admin on Fri Jun 25 21:11:36 UTC 2021 , Edited by admin on Fri Jun 25 21:11:36 UTC 2021
PRIMARY
MERCK INDEX
M8668
Created by admin on Fri Jun 25 21:11:36 UTC 2021 , Edited by admin on Fri Jun 25 21:11:36 UTC 2021
PRIMARY Merck Index
WIKIPEDIA
PHENYLEPHRINE
Created by admin on Fri Jun 25 21:11:36 UTC 2021 , Edited by admin on Fri Jun 25 21:11:36 UTC 2021
PRIMARY
INN
4174
Created by admin on Fri Jun 25 21:11:36 UTC 2021 , Edited by admin on Fri Jun 25 21:11:36 UTC 2021
PRIMARY
Related Record Type Details
TARGET -> AGONIST
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
BINDER->LIGAND
BINDING
SALT/SOLVATE -> PARENT
BASIS OF STRENGTH->SUBSTANCE
ASSAY (TITRATION)
EP
RACEMATE -> ENANTIOMER
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
Related Record Type Details
IMPURITY -> PARENT
For the calculation of contents, multiply the peak areas by 0.5
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
For the calculation of contents, multiply the peak areas by 0.5
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
UNSPECIFIED
EP
IMPURITY -> PARENT
UNSPECIFIED
EP
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Volume of Distribution PHARMACOKINETIC
Vdss PHARMACOKINETIC
Biological Half-life PHARMACOKINETIC